Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan

REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic so...

Full description

Saved in:
Bibliographic Details
Published in:Journal of intensive care 2021-04, Vol.9 (1), p.34-34, Article 34
Main Authors: Kamata, Kazuhiro, Jindai, Kazuaki, Ichihara, Nao, Saito, Hiroki, Kato, Hideaki, Kunishima, Hiroyuki, Shintani, Ayumi, Nishida, Osamu, Fujitani, Shigeki
Format: Article
Language:English
Subjects:
Bacterial pneumonia
Clinical trials
Collaboration
Coronaviruses
COVID-19
Embedded
Emerging infectious disease
Epidemics
Evidence-based medicine
Japan
Letter to the Editor
Medical colleges
Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia
Pandemics
Pneumonia
Randomized controlled trial
REMAP-CAP (Randomized
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies.
ISSN:2052-0492
2052-0492
DOI:10.1186/s40560-021-00547-7